Profiel
Hilde Hukkelberg currently works at Cytovation AS, as Independent Director from 2022 and SKAGEN AS, as Director from 2019.
Actieve functies van Hilde Hukkelberg
Bedrijven | Functie | Begin |
---|---|---|
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | Directeur/Bestuurslid | 01-03-2019 |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Directeur/Bestuurslid | 15-09-2022 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
SKAGEN AS
SKAGEN AS Investment ManagersFinance Part of Storebrand ASA, SKAGEN AS is a Norwegian fund management company. The company is based in Stavanger, Norway. SKAGEN was founded by Kristoffer Stensrud, Geir Tjetland, Åge Kristiansen Westbø, Tor Dagfinn Veen. Timothy Warrington has been the CEO of the company since 2007. | Finance |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Commercial Services |